To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
EQT and Goldman Sachs to buy Parexel for $8.5bn
EQT Private Equity and Goldman Sachs have agreed to acquire Parexel, a global clinical research organization, for $8.5 billion.
